Filer Snapshot

Sofinnova Crossover I

CIK 0001845105. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Company

Total filings

7

Latest filing

11 May 2026

Industry

n/a

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: 13D/G stake for ABVX. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Open 13D/G history Save page

Largest parsed holding

—

Populates from the latest parsed 13F information table.

Open holding

13D/G large stake

ABVX

07 May 2026 · 6.7% ownership

Open 13D/G

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it
Source: SEC Schedule 13D/G

SCHEDULE 13D/A filed on 11 May 2026 for CIK 0001845105.

View source filing
Ownership signals CIK-linked ownership evidence from parsed SEC filings. 1 signal
Parsed SEC ownership signals

Largest active 13D stakes

Active large-stake positions disclosed in parsed Schedule 13D filings.

ABVX

Largest active 13G stakes

Passive or institutional large-stake positions disclosed in parsed Schedule 13G filings.

IVA
How to read these SEC ownership signals
  • Read each filing family separately: 13F portfolios, 13D/G large stakes, and Forms 3/4/5 owner positions answer different SEC disclosure questions.
  • Open the linked research path when you need the filing, CIK, issuer, or CUSIP trail behind a value.
At a glance Names, identifiers, and filing context for this profile. 1 identity field
Business address
7 11 Boulevard Haussman, Paris, France, 75009
EDGAR profile Static EDGAR fields kept behind disclosure so the main profile stays readable. 1 profile field available
Fiscal year end
31 December

Filer intelligence

What SEC filings say about Sofinnova Crossover I

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Save filer

Quick read

  • 2 recent 13D/G stake rows found; top row is ABVX at 6.7% ownership.

SEC source mix

Counts show available parsed rows, not one combined ownership total.

XML parsed
13F portfolio No rows yet

Quarterly institutional portfolio holdings.

Open
13D/G stakes 2 rows

Beneficial ownership and large-stake disclosures.

Open
Forms 3/4/5 No rows yet

Officer, director, and 10% owner holdings or transactions.

Open

13D/G large-stake context

ABVX

07 May 2026 · Ordinary Shares, par value EUR0.01 per share

6.7%
Issuer page 13D/G history

IVA

31 Dec 2025 · Ordinary Shares, nominal value EUR0.01 per share

8.6%
Issuer page 13D/G history

Latest update

What changed recently for Sofinnova Crossover I

New filing available

Latest Schedule 13D/G period: 07 May 2026. Open the source-backed page to inspect the fresh filing or facts context.

Update date

11 May 2026

Page type

Filer profile

Latest period

07 May 2026

Schedule 13D/G context is visible from filings filed on 11 May 2026.

Open filer profile Browse recent public updates

Benchmark Context

Benchmark context for this company

Sofinnova Crossover I has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.

Compared with

Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.

Why this is notable

Latest Schedule 13D/G period: 07 May 2026. That gives you a fresh baseline before you compare this company with peers.

  • Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
  • Open the facts page first if you want the cleanest path to verification.

Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.

Open company facts Browse metric rankings

SEC filing record

CIK 0001845105 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
7
First seen
14 Feb 2025
Latest filing
11 May 2026
Entity
Company

Observed form types

SCHEDULE 13D/A SCHEDULE 13G/A

CIK-linked evidence first

Sofinnova Crossover I SEC filings Sofinnova Crossover I 13D/G history Open SEC filing index

Latest Filings

Showing the latest 7 of 7 SEC filings for Sofinnova Crossover I.

SCHEDULE 13D/A

SCHEDULE 13D/A filing

Filing date
11 May 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
17 Feb 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13D/A

SCHEDULE 13D/A filing

Filing date
14 Jan 2026
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13D/A

SCHEDULE 13D/A filing

Filing date
30 Oct 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13D/A

SCHEDULE 13D/A filing

Filing date
31 Jul 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13G/A

SCHEDULE 13G/A filing

Filing date
14 Feb 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
SCHEDULE 13D/A

SCHEDULE 13D/A filing

Filing date
14 Feb 2025
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .